CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer

∙ The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics 

∙ CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate  development and broaden application range of The RNA Printer® 

∙ Dr. Markus Bergmann appointed as General Manager for CureVac RNA Printer GmbH  

TÜBINGEN, Germany/ BOSTON, USA – March 1, 2022 – CureVac N.V. (Nasdaq: CVAC), a global  biopharmaceutical company developing a new class of transformative medicines based on  messenger ribonucleic acid (“mRNA”), today announced that it has established CureVac RNA  Printer GmbH, a fully-owned CureVac company to advance The RNA Printer®. The RNA Printer® is CureVac’s solution for integrated and automated manufacturing of GMP-grade RNA vaccines  and therapeutics. The new entity is designed as a platform and services company, providing a dedicated operational environment to further develop and establish The RNA Printer® as a  manufacturing end-to-end solution. This solution will include the main steps to manufacture  mRNA vaccines or therapeutics. The platform is designed to facilitate broad access to mRNA  technology and enable mRNA product developments, e.g. for rapid supply of new mRNA-based  vaccines in pandemic situations as well as patient access to advanced and personalized mRNA based therapies in oncology. The company will be led by Dr. Markus Bergmann, who joins  CureVac RNA Printer GmbH as General Manager on March 1, 2022. 

“The successful implementation of mRNA vaccines to address the COVID-19 pandemic has  shown the tremendous potential of this technology. We are convinced that the global mRNA  pipeline will grow strongly over the next decade,” said Dr. Franz-Werner Haas, Chief Executive  Officer of CureVac. “Providing access to flexible GMP manufacturing solutions is expected to be  a game changer for the speed with which new mRNA products can be advanced from lab to  clinic.” 

Dr. Franz-Werner Haas continues, “we warmly welcome Dr. Markus Bergmann as the CureVac  RNA Printer GmbH General Manager. His medical background as well as his experience in  developing targeted product strategies, transforming businesses and increasing business  efficiency – particularly in a high-tech field – represents a perfect fit and will create a strong  momentum for the next developmental stage of The RNA Printer®.” 

“The RNA Printer® is uniquely suited to further strengthen and increase CureVac’s footprint in  the rapidly expanding RNA space,” said Dr. Markus Bergmann. “The pioneering technology behind this platform has the potential to enable the translational step from science to innovative  products via an automated solution thereby broadening access to mRNA technology. I’m excited 

to be part of this technology advancement and to join this great team.” 

Dr. Bergmann joins CureVac RNA Printer GmbH from ZF Group, Germany, where he held various  management positions. He built his strong background in business development, product  management, finance, strategy and M&A via several leadership assignments including Rolls  Royce plc., UK, and McKinsey & Company, Germany and Asia. Dr. Bergmann started his career  as a doctor at the University Hospital in Tübingen, Germany, in the Department of Hematology 

and Oncology after graduating from University of Heidelberg, Germany, and receiving a Doctor  of Medicine in collaboration with the German Cancer Research Center in the field of  Immunology. 

About The RNA Printer® 

The RNA Printer® is CureVac’s solution for integrated and automated manufacturing of GMP grade RNA vaccines and therapeutics engineered in collaboration with Tesla Automation. The  system is powered by a proprietary and advanced manufacturing technology designed to cover  all steps for rapid and standardized manufacturing of mRNA medicines. The RNA Printer® aims  to facilitate broad access to mRNA technology and to accelerate the transition of innovative  products concepts from science to the clinic across different therapeutic areas, such as new  mRNA-based vaccines in pandemic situations as well as personalized mRNA-based therapies in  oncology. While The RNA Printer® will support CureVac’s clinical development programs,  CureVac RNA Printer GmbH will also explore opportunities to increase the versatility and  application of this technology together with external partners. 

About CureVac 

CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA)  technology, with more than 20 years of expertise in developing, optimizing and manufacturing  this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary  technology is the use of optimized mRNA as a data carrier to instruct the human body to produce  its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in  a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious  diseases based on CureVac’s second-generation mRNA technology. This collaboration was later  extended to the development of second-generation COVID-19 vaccine candidates, and modified  mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep  clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies,  and the treatment of rare diseases. CureVac had its initial public offering on the New York  Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and employs more than 900 people at its sites in Tübingen, Frankfurt, and Boston, USA.  

CureVac Investor Relations Contact 

Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations CureVac, Tübingen, Germany 

T: +49 7071 9883-1298 

M: +49 160 90 496949 

sarah.fakih@curevac.com 

CureVac Media Contact 

Bettina Jödicke-Braas, Manager Communications 

CureVac, Tübingen, Germany 

T: +49 7071 9883-1087 

bettina.joedicke-braas@curevac.com 

Forward-Looking Statements CureVac 

This press release contains statements that constitute “forward looking statements” as that  term is defined in the United States Private Securities Litigation Reform Act of 1995, including  statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or  projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac AG, CureVac Real  Estate GmbH, CureVac Inc., CureVac Swiss AG and CureVac Corporate Services GmbH (the  “company”) regarding future events or future results, in contrast with statements that reflect  historical facts. Examples include discussion of the potential efficacy of the company’s vaccine  and treatment candidates and the company’s strategies, financing plans, growth opportunities  and market growth. In some cases, you can identify such forward-looking statements by  terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or  “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of  these terms or similar expressions. Forward-looking statements are based on management’s  current beliefs and assumptions and on information currently available to the company.  However, these forward-looking statements are not a guarantee of the company’s performance,  and you should not place undue reliance on such statements. Forward-looking statements are  subject to many risks, uncertainties and other variable circumstances, including negative  worldwide economic conditions and ongoing instability and volatility in the worldwide financial  markets, ability to obtain funding, ability to conduct current and future preclinical studies and  clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third  parties and collaboration partners, ability to commercialize products, ability to manufacture any  products, possible changes in current and proposed legislation, regulations and governmental  policies, pressures from increasing competition and consolidation in the company’s industry, the  effects of the COVID-19 pandemic on the company’s business and results of operations, ability  to manage growth, reliance on key personnel, reliance on intellectual property protection,  ability to provide for patient safety, and fluctuations of operating results due to the effect of  exchange rates or other factors. Such risks and uncertainties may cause the statements to be  inaccurate and readers are cautioned not to place undue reliance on such statements. Many of  these risks are outside of the company’s control and could cause its actual results to differ  materially from those it thought would occur. The forward-looking statements included in this  press release are made only as of the date hereof. The company does not undertake, and  specifically declines, any obligation to update any such statements or to publicly announce the  results of any revisions to any such statements to reflect future events or developments, except  as required by law. 

For further information, please reference the company’s reports and documents filed with the  U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR  on the SEC website at www.sec.gov.